An in silico design of bioavailability for kinase inhibitors evaluating the mechanistic rationale in the CYP metabolism of erlotinib
Crossref DOI link: https://doi.org/10.1007/s00894-018-3917-z
Published Online: 2019-02-14
Published Print: 2019-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chelli, Sai Manohar
Gupta, Parth
Belliraj, Siva Kumar http://orcid.org/0000-0003-1257-4899
Text and Data Mining valid from 2019-02-14
Article History
Received: 17 August 2018
Accepted: 21 December 2018
First Online: 14 February 2019